Hello All, I completed a 12 week clinical trial of two meds in one pill from Merck. Grazoprevir is an improved pan genotypic protease inhibitor,
and Elbasvir is a NS5A inhibitor. These
Merck drugs should hit the market this Summer, I would think. The director of the clinical trial wrote me, and said the relapse rate of those in the clinical trials who achieved a SVR is 1%. It is worth noting that figure may change, as these meds are still so new.